As the COVID-19 pandemic continues to increase the death tolls, a need for a treatment is greater than ever. Serum institute CEO Adar Poonawala says they will proceed with human trials for a possible COVID-19 vaccine by year-end.
As the whole world is battling against the pandemic COVID-19, the medical industries have been working 24/7 on finding a vaccine to prevent the virus from causing further damage. Recently the World Health Organisation (WHO) has gone one record to state that vaccines are not to be expected for a minimum of 18 months. It was also stated that more than 40 vaccines are in different developmental stages.
Johnson & Johnson a leading pharmaceuticals stated that they had selected a candidate for the race against the pandemic. They have said to use the same technology they have used to develop a vaccine for ebola. The vaccine is said to moe tot the crucial human trials by the end of September and optimistically thinking ready for use by January of next year.
In other stories, Indian pharmaceuticals are also very keen on the race. Pune based Serum Institute has partnered with the prestigious biotechnology firm Codgenix to develop a vaccine expected to be ready by early 2022.
Adar Poonawala, CEO of Serum Institute went on record to say “It does take 6-7 years normally to make a vaccine. However, I think we should be able to go into human trials by the end of this year because we are entering into animal studies in about 3 weeks from today. So, that is very encouraging news and I can revise my earlier estimate from 2022 to maybe early next year.”
“We have also tried to make a vector vaccine using our Measles Schwartz strains with a company in the United States and that is about 3-4 months behind the Codagenix project. So, we are firing both these barrels which we have zeroed in on after a lot of conversations and we hope to put that candidate also in animals very soon, “he added.